Placental growth factor measurements in the assessment of women with suspected preeclampsia: a stratified analysis of the PARROT trial
- Resource Type
- Authors
- Jenny Myers; Chris Gale; Derek Tuffnell; Andrew Sharp; Nigel Simpson; Paul T. Seed; Kate E. Duhig; Lucy C Chappell; Joanna Girling; Kate Harding; Andrew Shennan
- Source
- Pregnancy Hypertension
Duhig, K E, Myers, J E, Gale, C, Girling, J C, Harding, K, Sharp, A, simpson, N A B, Tuffnell, D, Seed, P T, Shennan, A H & Chappell, L C 2021, ' Placental growth factor measurements in the assessment of women with suspected Preeclampsia : A stratified analysis of the PARROT trial ', Pregnancy Hypertension, vol. 23, pp. 41-47 . https://doi.org/10.1016/j.preghy.2020.10.005
- Subject
- Placental growth factor
pre-eclampsia/diagnosis
Disease
030204 cardiovascular system & hematology
biomarkers/blood
0302 clinical medicine
Pre-Eclampsia
Pregnancy
Medicine
Single-Blind Method
gestational age
humans
reproductive and urinary physiology
NICE, National Institute of Health and Care Excellence
030219 obstetrics & reproductive medicine
Obstetrics
adult
Pregnancy Outcome
Obstetrics and Gynecology
PlGF, placental growth factor
placenta growth factor/blood
female genital diseases and pregnancy complications
Diagnostic testing
female
Gestation
Female
pregnancy
Adult
medicine.medical_specialty
single-blind method
Hypertension in Pregnancy
Gestational Age
macromolecular substances
Article
Preeclampsia
Stratified analysis
03 medical and health sciences
Hypertension in pregnancy
Internal Medicine
Humans
pregnancy outcome/epidemiology
Preterm delivery
Placenta Growth Factor
business.industry
medicine.disease
PlGF
Small for gestational age
1114 Paediatrics and Reproductive Medicine
business
Biomarkers
- Language
- English
Highlights • Low PlGF at presentation with suspected preeclampsia identifies a severe phenotype of disease. • The use of PlGF testing leads to a reduction in severe maternal adverse outcomes. • PlGF testing increases antenatal surveillance of women at risk of complications of preeclampsia. • PlGF testing does not appear to cause an increase in preterm delivery rates.
Objective Placental growth factor testing decreases time to recognition of preeclampsia and may reduce severe maternal adverse outcomes. This analysis aims to describe the clinical phenotype of women by PlGF concentration, and to determine the mechanism(s) underpinning the reduction in severe maternal adverse outcomes in the PARROT trial, in order to inform how PlGF testing may be optimally used within clinical management algorithms. Study design This was a planned secondary analysis from the PARROT trial that compared revealed PlGF testing and management guidance with usual care in the assessment of women with suspected preterm preeclampsia. Main outcome measures Maternal and perinatal outcomes following stratification of women by trial group, and measured PlGF concentration. Results 1006 women were included. PlGF